GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Short Interest

OBI Pharma (ROCO:4174) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of OBI Pharma's Short Interest

For the Biotechnology subindustry, OBI Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OBI Pharma's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Short Interest falls into.


;
;

OBI Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Short Interest
Comparable Companies
TPE:6541 ROCO:6696 ROCO:6976 ROCO:6617 ROCO:6586 TPE:4142 ROCO:7759 ROCO:4162 TPE:6949 ROCO:4157 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 508, Section. 7, Zhongxiao East Road, 6th Floor, Nangang District, Taipei, TWN, 115011
Website
https://www.obipharma.com
OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.

OBI Pharma Headlines

No Headlines